Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.1K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

234
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
234

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome of metastatic non-rhabdomyosarcoma soft tissue sarcoma in children and young adults treated on children's oncology group ARST0332 trial.

Journal of the National Cancer Institute·2026
Same author

Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.

British journal of cancer·2026
Same author

Experiences of racially, ethnically, sexual- and gender-minoritized adolescents and young adults with cancer in the Canadian health care system.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Top 10 research priorities for adolescent and young adult cancer in Canada: a James Lind Alliance priority setting partnership.

BMJ open·2026
Same author

A Real-World Analysis of Outcomes in CIC-Rearranged Sarcomas: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) Study.

Cancer medicine·2026
Same author

Incidence and Outcome of Infants With Cancer in Canada: A Report From Cancer in Young People in Canada Database.

Pediatric blood & cancer·2025

Related Experiment Video

Updated: Jan 7, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.6K

Update on pediatric soft tissue sarcomas.

Jamie Aye1,2, Jacquelyn Crane3,4, Sapna Oberoi5,6

  • 1Children's of Alabama.

Current Opinion in Pediatrics
|December 26, 2025
PubMed
Summary

Recent advances in pediatric soft tissue sarcomas (STS) refine risk stratification and identify new therapeutic targets. Genomic insights are crucial for improving outcomes in these rare childhood cancers.

Keywords:
adolescentschildrenrhabdomyosarcomasoft tissue sarcomatreatment

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.9K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.2K

Related Experiment Videos

Last Updated: Jan 7, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.6K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.9K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.2K

Area of Science:

  • Pediatric oncology
  • Cancer genomics
  • Sarcoma biology

Background:

  • Soft tissue sarcomas (STS) are rare and diverse pediatric malignancies.
  • Understanding the underlying biology is key to improving treatment outcomes.

Purpose of the Study:

  • To review recent advancements in the diagnosis, biology, risk stratification, and treatment of pediatric STS.
  • To highlight the impact of genomic discoveries on clinical management.

Main Methods:

  • Literature review of recent findings in pediatric soft tissue sarcomas.
  • Analysis of prognostic factors and therapeutic targets in rhabdomyosarcoma and other STS subtypes.

Main Results:

  • FOXO1 fusion status is a key prognostic factor in rhabdomyosarcoma (RMS).
  • TP53 and MYOD1 mutations, and circulating tumor DNA impact survival in intermediate-risk RMS.
  • Maintenance therapy improved survival in the RMS2005 trial.
  • Targeted therapies like atezolizumab, larotrectinib, and tazemetostat show promise in specific pediatric STS subtypes.

Conclusions:

  • Pediatric STS are biologically heterogeneous, necessitating tailored treatment approaches.
  • Genomic advances are improving risk stratification and uncovering novel therapeutic targets.
  • International collaboration and clinical trials are essential for future progress in pediatric STS treatment.